Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-11-17
1997-12-02
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 4, 514 12, 514 13, 530303, 530324, 530326, A61K 3828, C07K 1462
Patent
active
056936095
ABSTRACT:
The present invention relates to the field of diabetes. More particularly, the invention relates to a monomeric insulin analog wherein the A chain is the naturally occurring sequence of the human insulin A chain and the B chain is modified at either position B28 and B29 or both. The analog is mono-acylated at the N-terminal of the A chain or B chain or at the lysine. The acylated insulin analogs have an extended duration of action.
REFERENCES:
patent: 3823125 (1974-07-01), Grant et al.
patent: 3864325 (1975-02-01), Smyth
patent: 3868356 (1975-02-01), Smyth
patent: 3868357 (1975-02-01), Smyth et al.
patent: 3869437 (1975-03-01), Lindsay et al.
patent: 3950517 (1976-04-01), Lindsay et al.
Hashimoto, et al, Pharmaceutical Research, 6:2, 171-176, (1989).
Scheider, Journal of Physical Chemistry, 84:8, 925-928, (1980).
Geiger, et al., Biological Activity of Insulin Analoques Substituted at the Amino Group of B1-Phenylalanine, from Proceedings of the Second International Insulin Symposium, Aachen, Germany, Sep. 4-7, 409-415, (1979).
R. Geiger and R. Obermeier, Contribution of peptide chemistry to our knowledge of insulin and diabetes, from Proceedings of the Symposium on Proinsulin, Insulin and C-Peptide, Tokushima, 12-14 Jul., 62-72, (1978).
Rosen, et al, A1-Modified Insulins: Receptor Binding and Biological Activity, from Proceedings of the Second International Insulin Symposium, Aachen, Germany, Sep. 4-7, 403-408, (1979).
D.G. Lindsay and S. Shall, Biochem.J., 115, 587-595, (1969).
Muranishi, et al., Journal of Controlled Release, 19, 179-188, (1992).
Hashizume, et al., J. Pharm. Pharmacol., 44 555-559, (1992).
D.L. Lindsay and S. Shall, Biochem.J., 121, 737-745, (1971).
Lapidot, et al., Journal of Lipid Research, 8, 142-145, (1967).
Asada, et al., Pharmaceutical Research, 11:8, 1115-1120, (1994).
Inoue, et al., Biochemistry, 28:16, 6619-6624, (1989).
Kunitomo, et al., The Journal of Biological Chemistry, 267:13, 8732-8738, (1992).
Brem et al. (1992) Protien Engineering vol. 5 No. 6 pp. 527-533.
Carey, Francis A. (1987) Organic Chemistry. McGraw-Hill Book Company pp. 1110-1113.
Baker Jeffrey C.
Hanquier Jose M.
Boone David E.
Caltrider Steven P.
Eli Lilly and Company
Gupta Anish
Tsang Cecilia J.
LandOfFree
Acylated insulin analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Acylated insulin analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acylated insulin analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-801280